المؤلفون: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, P. V. Kononets

المصدر: Южно-Российский онкологический журнал, Vol 5, Iss 3, Pp 31-38 (2024)

مصطلحات موضوعية: metastatic renal cell carcinoma, overall survival rate, elderly patients, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.cancersp.com/jour/article/view/283; https://doaj.org/toc/2686-9039

URL الوصول: https://doaj.org/article/4045e209c99d4b8299f3281263e3be85

المؤلفون: D. V. Semyonov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, N. A. Karlova

المصدر: Сибирский онкологический журнал, Vol 23, Iss 2, Pp 37-46 (2024)

مصطلحات موضوعية: renal cell cancer, lung metastases, overall survival, prognostic factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.siboncoj.ru/jour/article/view/3037; https://doaj.org/toc/1814-4861; https://doaj.org/toc/2312-3168

URL الوصول: https://doaj.org/article/ecf80b3b23a54a1d913bb9c671d3cd4f

المؤلفون: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, M. I. Gluzman, Yu. S. Korneva

المصدر: Сибирский онкологический журнал, Vol 23, Iss 1, Pp 53-62 (2024)

مصطلحات موضوعية: oligometastatic renal cell cancer, cytoreductive nephrectomy, metastasectomy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.siboncoj.ru/jour/article/view/2964; https://doaj.org/toc/1814-4861; https://doaj.org/toc/2312-3168

URL الوصول: https://doaj.org/article/ae24353288e240e99eadf564c6109acb

المؤلفون: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, M. I. Gluzman, S. G. Grigoriev, Yu. S. Korneva

المصدر: Вестник урологии, Vol 11, Iss 2, Pp 110-121 (2023)

مصطلحات موضوعية: metastatic renal cell carcinoma, prognosis, intermediate, international mrcc database consortium (imdc), overall survival, post-progression survival, Diseases of the genitourinary system. Urology, RC870-923

وصف الملف: electronic resource

Relation: https://www.urovest.ru/jour/article/view/726; https://doaj.org/toc/2308-6424

URL الوصول: https://doaj.org/article/575c1dc3bf704219bccaa1194e941fd6

المؤلفون: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, S. G. Grigoriev, Yu. S. Korneva

المصدر: Вестник урологии, Vol 10, Iss 3, Pp 65-73 (2022)

مصطلحات موضوعية: renal cell carcinoma, metastases, synchronous, metachronous, systemic therapy, Diseases of the genitourinary system. Urology, RC870-923

وصف الملف: electronic resource

Relation: https://www.urovest.ru/jour/article/view/582; https://doaj.org/toc/2308-6424

URL الوصول: https://doaj.org/article/0ec59ae89ed541c49501ecd757cb9018

المؤلفون: O. V. Leonov, V. T. Dolgikh, V. N. Lukach, V. I. Shirokorad, D. I. Demin, Ye. I. Kopyltsov, I. A. Volodin, D. V. Dolgikh

المصدر: Бюллетень сибирской медицины, Vol 2, Iss 4, Pp 66-72 (2003)

مصطلحات موضوعية: рак предстательной железы, эпидуральная аналгезия, интратекальная гормонотерапия, Medicine

وصف الملف: electronic resource

Relation: https://bulletin.ssmu.ru/jour/article/view/3809; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684

URL الوصول: https://doaj.org/article/29b4433defdd4d77bdbb5349ae913216

المؤلفون: V. I. Shirokorad, A. A. Izmailov, D. G. Lupashko, В. И. Широкорад, А. А. Измайлов, Д. Г. Лупашко

المصدر: Cancer Urology; Том 20, № 1 (2024); 52-59 ; Онкоурология; Том 20, № 1 (2024); 52-59 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: метастаз-направленная терапия, salvage lymph node dissection, nodal oligorecurrence, metastasis-targeting therapy, спасительная лимфаденэктомия, олигометастатический рак

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1755/1515; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Suardi N., Porter C.R., Reuther A.M. et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer;112(6):1254–63. DOI:10.1002/cncr.23293; Morris M.J., Rowe S.P., Gorin M.A. et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 2021;27(13):3674–82. DOI:10.1158/1078-0432.CCR-20-4573; Fendler W.P., Calais J., Eiber M. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019;5(6):856–63. DOI:10.1001/jamaoncol.2019.0096; Trock B.J., Han M., Freedland S.J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299(23):2760–9. DOI:10.1001/jama.299.23.2760; Tendulkar R.D., Agrawal S., Gao T. et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016;34(30):3648–54. DOI:10.1200/JCO.2016.67.9647; Pollack A., Karrison T., Balogh A. et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. Int J Radiat Oncol Biol Phys 2018;102(5):1605. DOI:10.1016/j.ijrobp.2018.08.052; Suardi N., Gallina A., Lista G. et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 2014;65(3):546–51. DOI:10.1016/j.eururo.2013.01.027; Fossati N., Karnes R.J., Boorjian S.A. et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol 2017;71(6):886–93. DOI:10.1016/j.eururo.2016.07.028; Nguyen P.L., Alibhai S.M., Basaria S. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67(5):825–36. DOI:10.1016/j.eururo.2014.07.010; Ploussard G., Gandaglia G., Borgmann H. et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol 2019;76(4):493–504. DOI:10.1016/j.eururo.2018.10.041; Sivaraman A., Benfante N., Touijer K. et al. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer? Investig Clin Urol 2018;59(2):83–90. DOI:10.4111/icu.2018.59.2.83; Нюшко К.М., Крашенинников А.А., Сергиенко С.А. и др. Результаты спасительной лимфаденэктомии у больных раком предстательной железы после радикального лечения. Исследования и практика в медицине 2017;4(S1):87.; Brassetti A., Proietti F., Pansadoro V. Oligometastatic prostate cancer and salvage lymph node dissection: systematic review. Minerva Chir 2019;74(1):97–106. DOI:10.23736/S0026-4733.18.07796-9; Измайлов А.А., Шкурников М.Ю., Алексеев Б.Я. Молекулярно-генетические методики выявления метастазов в лимфатических узлах у больных раком предстательной железы. Онкология. Журнал им. П.А. Герцена 2023;12(4):74–7. DOI:10.17116/onkolog20231204174; https://oncourology.abvpress.ru/oncur/article/view/1755

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1755
https://doi.org/10.17650/1726-9776-2024-20-1-52-59

المؤلفون: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritskiy, M. I. Gluzman, Yu. S. Korneva, Д. В. Семенов, Р. В. Орлова, В. И. Широкорад, С. В. Кострицкий, М. И. Глузман, Ю. С. Корнева

المصدر: Cancer Urology; Том 19, № 3 (2023); 31-44 ; Онкоурология; Том 19, № 3 (2023); 31-44 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: системная терапия, cytoreductive nephrectomy, overall survival, IMDC risk group, systemic therapy, циторедуктивная нефрэктомия, общая выживаемость, группа прогноза по IMDC

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1687/1477; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1310; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1311; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1312; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1313; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1314; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1315; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1316; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1317; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1318; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1319; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1320; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1321; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1322; Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75(1):74-84. DOI:10.1016/j.eururo.2018.08.036; Ljungberg B., Albiges L., Abu-Ghanem Y. et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019;75(5):799-810. DOI:10.1016/j.eururo.2019.02.011; Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655-9. DOI:10.1056/NEJMoa003013; Mickisch G.H., Garin A., van Poppel H. et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966-70. DOI:10.1016/s0140-6736(01)06103-7; Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3):1071-6. DOI:10.1097/01.ju.0000110610.61545.ae; Heng D.Y., Wells J.C., Rini B.I. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66(4):704-10. DOI:10.1016/j.eururo.2014.05.034; Mejean A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379(5):417-27. DOI:10.1056/NEJMoa1803675; Bex A., Mulders P., Jewett M. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5(2):164-70. DOI:10.1001/jamaoncol.2018.5543; Motzer R.J., Jonasch E., Michaelson M.D. et al. NCCN Guidelines Insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw 2019;17(11):1278-85. DOI:10.6004/jnccn.2019.0054; Xiao W.J., Zhu Y., Dai B. et al. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a SEER analysis. Int Braz J Urol 2015;41(2):288-95. DOI:10.1590/s1677-5538.IBJU.2015.02.15; Hanna N., Sun M., Meyer C.P. et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study. J Clin Oncol 2016;34(27):3267-75. DOI:10.1200/JCO.2016.66.7931; Arora S., Sood A., Dalela D. et al. Cytoreductive nephrectomy: assessing the generalizability of the CARMENA trial to real-world national cancer data base cases. Eur Urol 2019;75(2):352-3. DOI:10.1016/j.eururo.2018.10.054; Bhindi B., Abel E.J., Albiges L. et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 2019;75(1):111-28. DOI:10.1016/j.eururo.2018.09.016; Singla N., Hutchinson R.C., Ghandour R.A. et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol 2020;38(6):604.e9-17. DOI:10.1016/j.urolonc.2020.02.029; I.N. Group SO. Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE trial (PROBE).; Deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: The NORDIC-SUN-Trial (NORDIC-SUN). Sponsor: Donskov F., Aarhus University Hospital. DOI:10.31525/ct1-nct03977571; Mejean A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80(4):417-24. DOI:10.1016/j.eururo.2021.06.009; Kato R., Naito S., Numakura K. et al. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. Int J Clin Oncol 2022;27(3):563-73. DOI:10.1007/s10147-021-02091-8; Esagian S.M., Ziogas I.A., Kosmidis D. et al. Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a systematic review and individual patient data meta-analysis. Cancers (Basel) 2021;13(4):695. DOI:10.3390/cancers13040695; Bhindi B., Graham J., Wells J.C. et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur Urol 2020;78(4):615-23. DOI:10.1016/j.eururo.2020.04.038; De Bruijn R., Wimalasingham A., Szabados B. et al. Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data. Eur Urol Oncol 2020;3(2):168-73. DOI:10.1016/j.euo.2019.12.004; Bakouny Z., El Zarif T., Dudani S. et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. Eur Urol 2022;83(2):145-51. DOI:10.1016/j.eururo.2022.10.004; Westerman M.E., Shapiro D.D., Tannir N.M. et al. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int 2020;126(6):745-53. DOI:10.1111/bju.15160; Mori K., Quhal F., Yanagisawa T. et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis. Int Immunopharmacol 2022;108:10872. DOI:10.1016/j.intimp.2022.108720; https://oncourology.abvpress.ru/oncur/article/view/1687

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1687
https://doi.org/10.17650/1726-9776-2023-19-3-31-44

المؤلفون: V. I. Shirokorad, В. И. Широкорад

المصدر: Cancer Urology; Том 19, № 3 (2023); 104-112 ; Онкоурология; Том 19, № 3 (2023); 104-112 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: радий-223, poor prognosis group, bones metastasis, palliative external beam radiotherapy for primary tumor, radionuclide therapy, radium-223, группа неблагоприятного прогноза, костный метастаз, паллиативная лучевая терапия на первичную опухоль, радионуклидная терапия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1659/1475; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1659/1366; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1659/1367; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Boevé L.M.S., Hulshof M.C.C.M., Vis A.N. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 2019;75(3):410–8. DOI:10.1016/j.eururo.2018.09.008; Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397–406. DOI:10.1016/S1470-2045(14)70474-7; Parker C., Nilsson S., Heinrich D. et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI:10.1056/NEJMoa1213755; Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306–16. DOI:10.1016/S1470-2045(16)30173-5; Smith M.R., Parker C.C., Saad F. et al. ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). ESMO Congress Oct 19–23, 2018, Munich, Germany. Annal Oncol 2018;29(suppl_8). DOI:10.1093/annonc/mdy424.035; https://oncourology.abvpress.ru/oncur/article/view/1659

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1659
https://doi.org/10.17650/1726-9776-2023-19-3-104-112

المؤلفون: V. I. Shirokorad, В. И. Широкорад

المصدر: Cancer Urology; Том 18, № 4 (2022); 134-135 ; Онкоурология; Том 18, № 4 (2022); 134-135 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: тазовые расстройства, метастатическое поражение костей, светлоклеточный почечноклеточный рак, неврологическая симптоматика

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1651/1425; https://oncourology.abvpress.ru/oncur/article/view/1651

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1651
https://doi.org/10.17650/1726-9776-2022-18-4-134-135

المؤلفون: S. V. Kostritskiy, V. I. Shirokorad, B. Ya. Alekseev, D. V. Semenov, A. S. Kalpinskiy, Yu. S. Korneva, С. В. Кострицкий, В. И. Широкорад, Б. Я. Алексеев, Д. В. Семенов, А. С. Калпинский, Ю. С. Корнева

المساهمون: The study was performed without external funding., Исследование проведено без спонсорской поддержки.

المصدر: Cancer Urology; Том 18, № 3 (2022); 41-50 ; Онкоурология; Том 18, № 3 (2022); 41-50 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: тактика ведения, bone metastasis, oligo metastasis, management tactics, костный метастаз, олигометастаз

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1561/1394; Dudani S., de Velasco G., Wells J.C. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4;4(1):e2021869. DOI:10.1001/jamanetworkopen.2020.21869; Wood S.L., Brown J.E. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 2012;38(4):284–91. DOI:10.1016/j.ctrv.2011.06.011; Owari T., Miyake M., Nakai Y. et al. Clinical features and risk factors of skeletal-related events in genitourinary cancer patients with bone metastasis: a retrospective analysis of prostate cancer, renal cell carcinoma, and urothelial carcinoma. Oncology 2018;95(3):170–8. DOI:10.1159/000489218; Milano M.T., Biswas T., Simone C.B.2nd, Lo S.S. Oligometastases: history of a hypothesis. Ann Palliat Med 2021;10(5):5923–30. DOI:10.21037/apm.2020.03.31; Okuno Y., Tanaka R., Mikami K., Takeuchi T. Renal cancer tissue after nivolumab/ipilimumab combination therapy for metastatic renal cell carcinoma. Hinyokika Kiyo 2020;66(1):13–7. DOI:10.14989/ActaUrolJap_66_1_13; Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4): 618–29. DOI:10.1016/j.eururo.2016.08.003; Семков А.С., Махсон А.Н., Петерсон С.Б. и др. Хирургическое лечение костных метастазов рака почки. Онкоурология 2010;6(4):10–5. DOI:10.17650/1726-9776-2010-6-4-10-15; Mendez L.C., Raman S., Wan B.A. et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC-QLQ-C30 and EORTC-QLQ-BM22: results of a Brazilian cohort. Ann Palliat Med 2017;6(Suppl. 1):S65–70. DOI:10.21037/apm.2017.04.06; Azawi N.H., Tesfalem H., Dahl C., Lund L. Do the different types of renal surgery impact the quality of life in the postoperative period? Int Urol Nephrol 2015;47(2):263–9. DOI:10.1007/s11255-014-0893-9; De Groot S., Redekop W.K., Versteegh M.M. et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res 2018;27(1):115–24. DOI:10.1007/s11136-017-1704-4; Zhao W., Wang H., Hu J.H. et al. Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis. Jpn J Clin Oncol 2018;48(8):753–9. DOI:10.1093/jjco/hyy090; Herrmann E., Gerss J., Bierer S. et al. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol 2009;135(1):61–7. DOI:10.1007/s00432-008-0438-7; https://oncourology.abvpress.ru/oncur/article/view/1561

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1561
https://doi.org/10.17650/1726-9776-2022-18-3-41-50

المؤلفون: V. I. Shirokorad

المصدر: Onkourologiâ, Vol 16, Iss 4 (2020)

مصطلحات موضوعية: Medicine

Relation: https://oncourology.abvpress.ru/oncur/article/view/1417; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/cc5479a83852423495ef3d057238485b

الاتاحة: https://doi.org/10.17650/1726-9776-2020-16-4-213
https://doaj.org/article/cc5479a83852423495ef3d057238485b

المؤلفون: V. I. Shirokorad, V. V. Kapustin, В. И. Широкорад, В. В. Капустин

المصدر: Cancer Urology; Том 15, № 1 (2019); 75 ; Онкоурология; Том 15, № 1 (2019); 75 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-1

مصطلحات موضوعية: мультипараметрическая МРТ, биопсия простаты, таргетная биопсия, осложнения

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/932/840; https://oncourology.abvpress.ru/oncur/article/view/932

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/932
https://doi.org/10.17650/1726-9776-2019-15-1-75

المؤلفون: V. I. Shirokorad, S. V. Kostritskii, N. S. Zaborovskiy, D. A. Ptashnikov

المصدر: Onkourologiâ, Vol 13, Iss 2, Pp 43-48 (2017)

مصطلحات موضوعية: kidney cancer, metastas of renal cell carcinoma in the spine, targeted therapy, surgical treatment, survival, Medicine

Relation: https://oncourology.abvpress.ru/oncur/article/view/637; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/b0f7c9e5a06749caaa7c100ae2d5885e

الاتاحة: https://doi.org/10.17650/1726-9776-2017-13-2-43-48
https://doaj.org/article/b0f7c9e5a06749caaa7c100ae2d5885e

المؤلفون: V. I. Shirokorad

المصدر: Onkourologiâ, Vol 13, Iss 1, Pp 139-146 (2017)

مصطلحات موضوعية: prostate cancer, bone metastases, prostatektomiya, Medicine

Relation: https://oncourology.abvpress.ru/oncur/article/view/600; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/81d9530f9d684035a7853dd704bfc5db

الاتاحة: https://doi.org/10.17650/1726-9776-2017-13-1-139-146
https://doaj.org/article/81d9530f9d684035a7853dd704bfc5db

المؤلفون: V. I. Shirokorad, A. N. Makhson, I. G. Rusakov, G. P. Kolesnikov, S. V. Kostritskiy, K. Yu. Kashintsev, V. I. Borisov, M. I. Popov, M. Yu. Shchupak, N. V. Kirdakova, S. V. Mishugin, M. R. Maturov, A. G. Vinogradskiy, S. D. Shikhov, E. V. Gaydamaka, N. A. Apol’skaya, M. U. Shushakov, E. R. Babaev, A. A. Vorontsova, A. M. Ivanov, F. R. Amosov, В. И. Широкорад, А. Н. Махсон, И. Г. Русаков, Г. П. Колесников, С. В. Кострицкий, К. Ю. Кашинцев, В. И. Борисов, М. И. Попов, М. Ю. Щупак, Н. В. Кирдакова, С. В. Мишугин, М. Р. Матуров, А. Г. Виноградский, С. Д. Шихов, Е. В. Гайдамака, Н. А. Апольская, М. У. Шушаков, Э. Р. Бабаев, А. А. Воронцова, А. М. Иванов, Ф. Р. Амосов

المصدر: Cancer Urology; Том 12, № 2 (2016); 14-17 ; Онкоурология; Том 12, № 2 (2016); 14-17 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-2

مصطلحات موضوعية: метастазы, targeted therapy, metastases, таргетная терапия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/570/542; https://oncourology.abvpress.ru/oncur/article/view/570/558; Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 2008 г. Вестник РОНЦ им. Н.Н. Блохина 2010;(2):48–9. [Davydov М.I., Аksel’ Е.М. Morbidity and fatality, caused by malignant neoplasms to the population of CIS countries in 2008. Herald of N.N. Blokhin RCRC 2010;(2): 48–9. (In Russ.)].; Алексеев Б.Я., Анжиганова Ю.В., Лыков А.В. и др. Особенности диагностики и лечения рака почки в России: предварительные результаты многоцентрового ко оперированного исследования. Онкоурология 2012;(3):24–31. [Аlekseev B.Ya., Аnzhiganovа Yu.V., Lykov А.V. et al. Peculiarities of the diagnostics and treatment of the kidney cancer in Russia: preliminary results of the multicenter cooperated studies. Оnkourologiya = Cancer Urology 2012;(3):24–31. (In Russ.)].; Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2014 году. М., 2015. 236 с. [Kaprin А.D., Starinskiy V.V., Petrova G.V. Status of oncologic assistance to the population of Russia in 2014. Мoscow, 2015. 236 p. (In Russ.)].; Матвеев В.Б., Волкова М.И. Последовательная таргетная терапия при диссеминированном раке почки. Онкоурология 2013;(1):28–33. [Маtveev V.B., Volkova М.I. Consecutive target therapy at the disseminated kidney cancer. Оnkourologiya = Cancer Urology 2013;(1):28–33. (In Russ.)].; Широкорад В.И., Махсон А.Н. Первые результаты таргетной терапии при раке почки в Москве. Онкоурология 2013;(3):24–9. [Shirokorad V.I., Мakhson A.N. First results of target therapy at the kidney cancer in Moscow. Оnkourologiya = Cancer Urology 2013;(3):24–9. (In Russ.)].; Motzer R.J., Hutson T., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90.; Hass N.B., Manola J., Uzzo R.G. et al. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol 2015; 33 Suppl 7:abstr 403.; Алексеев Б.Я., Калпинский А.С. Применение таргетных препаратов в лечении метастатического рака почки: последовательное назначение или комбинация. Онкоурология 2010;(4):16–22. [Аlekseev B.Ya., Kalpinskiy А.S. Application of target substances in the treatment of the metastatic kidney cancer: consecutive administration or combination. Оnkourologiya = Cancer Urology 2010;(4):16–22. (In Russ.)].; https://oncourology.abvpress.ru/oncur/article/view/570

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/570
https://doi.org/10.17650/1726-9776-2016-12-2-14-17

المؤلفون: G. P. Kolesnikov, I. G. Rusakov, A. A. Gritskevich, S. V. Mishugin, V. I. Shirokorad, N. V. Kirdakova, D. G. Sokov, A. A. Vorontsova, Г. П. Колесников, И. Г. Русаков, А. А. Грицкевич, С. В. Мишугин, В. И. Широкорад, Н. В. Кирдакова, Д. Г. Соков, А. А. Воронцова

المصدر: Malignant tumours; № 1 (2016); 28-34 ; Злокачественные опухоли; № 1 (2016); 28-34 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: сердечно-сосудистая патология, degrelix, cardiovascular pathology, дегареликс

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/223/213; Albertsen P.C., Klotz L., Tombal B. et al. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. Eur Urol 2014;65:565–73.; Anderson J., Abrahamsson P.A., Crawford D., et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int 2008;101:1497–1501.; Bosco C, et al. Eur Urol 2014, in press materials.; Gandaglia G, et al. Clin Genitourin Cancer. 2015;13(3): 123–30.; Keating, et al. J Natl Can Inst 2010;102:39–46.; Kurt Miller Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). Ther Adv Urol 2015, Vol. 7(3) 105–115.; Nanda A, et al. JAMA 2009;302:866–73; 4.; Mottet N, et al. 2014 EAU Guidelines on prostate cancer.; Мишугин С.В., Колесников Г.П., Широкорад В.И. Результаты Российского проспективного исследования по оценке эффективности и переносимости дегареликса у больных раком предстательной железы. Онкология. Журнал им. П.А. Герцена, 1, 2015, 45–49. S.V. Mishugin, G.P. Kolesnikov, V. I. Shirokorad Results of Russian Prospective Study for Assessment of Degarelix Efficacy and Tolerance in Patients with Prostate Cancer. P.A. Hertzen Oncology. Journal, 1, 2015, 45–49.; https://www.malignanttumors.org/jour/article/view/223

الاتاحة: https://www.malignanttumors.org/jour/article/view/223
https://doi.org/10.18027/2224-5057-2016-1-28-34

المؤلفون: V. I. Shirokorad, G. P. Kolesnikov, S. V. Kostritskiy, K. Yu. Kashintsev, D. V. Dolgikh

المصدر: Onkourologiâ, Vol 12, Iss 3, Pp 30-39 (2016)

مصطلحات موضوعية: kidney cancer, sequential targeted therapy, metastases, tyrosine kinase inhibitors, Medicine

Relation: https://oncourology.abvpress.ru/oncur/article/view/563; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/ec19eae5879b403bb83e9e91a127b4aa

الاتاحة: https://doi.org/10.17650/1726-9776-2016-12-3-30-39
https://doaj.org/article/ec19eae5879b403bb83e9e91a127b4aa

المؤلفون: A. I. Gromov, V. I. Shirokorad, V. V. Kapustin, V. P. Sergeev

المصدر: Onkourologiâ, Vol 4, Iss 2, Pp 26-30 (2020)

مصطلحات موضوعية: Medicine

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doajarticles::fceae00a069fd5ffdae91a1c1fd9348a
https://oncourology.abvpress.ru/oncur/article/view/1097

المؤلفون: V. V. Kapustin, V. I. Shirokorad, M. B. Anahasyan

المصدر: Onkourologiâ, Vol 4, Iss 1, Pp 15-18 (2020)

مصطلحات موضوعية: Medicine

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doajarticles::2bae0130196042fc9708995dc5433730
https://oncourology.abvpress.ru/oncur/article/view/1029